Skip to Main Content

Paper Details

Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
Cancer Cell
42
2022
TMB, germline, non-small cell lung cancer, patient, patients, solid tumors, tumor
Author NameAffiliation
Robert I HaddadDana-Farber Cancer Institute
Robert I HaddadDana-Farber Cancer Institute
Noah ZaitlenDavid Geffen School of Medicine, University of California los angeles
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center, USA Marie-Josee and Henry R. Kravis Center for Molecular Oncology
Laura E MacConaillBrigham and Women's Hospital, USA Center for Cancer Genome Discovery, Dana-Farber Cancer Institute
Toni K ChoueiriLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Deborah SchragMemorial Sloan Kettering Cancer Center
  • 1 - 9

Datasets

Release 1.2